Bottom line
VHT vs GGHCX: the short answer
VHT (Vanguard Health Care Index Fund) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 54% by weight.
But VHT is far broader, holding 407 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.
VHT is cheaper at 0.09% vs 1.07% — a difference of $98 a year per $10,000 invested.
Over five years, VHT returned +7.2% a year vs +2.6% for GGHCX (reporting dates differ).
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
VHT vs GGHCX side by side
| VHT | GGHCX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Vanguard | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.09% | 1.07% |
| Annual cost per $10k | $9 | $107 |
| 10-yr cost on $10k (prospectus) | $115 | $1,784 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +2.7% | +9.2% |
| 5-yr return (annualized) | +7.2% | +2.6% |
| 10-yr return (annualized) | +8.8% | +5.8% |
| Best quarter | +16.5% | +19.6% |
| Worst quarter | −13.1% | −16.5% |
| Net assets (fund) | $19.0B | $1.2B |
| Number of holdings | 407 | 82 |
| Portfolio turnover | 4% | 59% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | VHT | GGHCX | Difference |
|---|---|---|---|
| 2024 | +2.7% | +4.0% | −1.3% |
| 2023 | +2.5% | +3.1% | −0.6% |
| 2022 | −5.5% | −13.5% | +8.0% |
| 2021 | +20.5% | +12.2% | +8.3% |
| 2020 | +18.2% | +14.5% | +3.8% |
| 2019 | +22.0% | +32.0% | −10.0% |
| 2018 | +5.6% | +0.5% | +5.1% |
| 2017 | +23.3% | +15.5% | +7.9% |
| 2016 | −3.3% | −11.7% | +8.4% |
Source: Fund prospectus bar charts
Holdings overlap
10 of VHT's top 25 holdings also appear in GGHCX's top 25.
| Holding | VHT | GGHCX |
|---|---|---|
| Eli Lilly & Co | 14.04% | 10.59% |
| Johnson & Johnson | 8.47% | 6.76% |
| AbbVie Inc | 6.09% | 4.03% |
| UnitedHealth Group Inc | 5.45% | 6.17% |
| Merck & Co Inc | 4.66% | 4.59% |
| Thermo Fisher Scientific Inc | 2.93% | 1.55% |
| Gilead Sciences Inc | 2.64% | 3.63% |
| CVS Health Corp | 1.83% | 2.52% |
| Vertex Pharmaceuticals Inc | 1.80% | 2.01% |
| Edwards Lifesciences Corp | 0.79% | 1.56% |
Source: SEC Form N-PORT
VHT top 10
- Eli Lilly & Co — 14.04%
- Johnson & Johnson — 8.47%
- AbbVie Inc — 6.09%
- UnitedHealth Group Inc — 5.45%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 2.93%
- Amgen Inc — 2.87%
- Gilead Sciences Inc — 2.64%
- Intuitive Surgical Inc — 2.38%
- Pfizer Inc — 2.35%
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
FAQ
What is the difference between VHT and GGHCX?
Which is cheaper, VHT or GGHCX?
Should I own both VHT and GGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.